Men with HIV who are on testosterone therapy appear to have an elevated risk for significant coronary artery calcium progression (CAC) vs those who are not on it, according to a study released at CROI 20.
A once-weekly tuberculosis (TB) prevention regimen of isoniazid 900 mg and rifapentine 900 mg given for 3 months (3HP) resulted in higher treatment completion rates vs isoniazid daily for 6 months (6H) in patients with HIV receiving antiretroviral therapy (ART), a study released at CROI 2020 has shown.
The combination of dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) has superior virologic efficacy and safety compared with an efavirenz (EFV)/FTC/tenofovir disoproxil fumarate (TDF) combination in pregnant women living with HIV (WLHIV), results of the IMPAACT 2010/VESTED* trial showed.
The second HIV patient to successfully undergo stem cell transplantation is still in remission, a good 30 months after stopping antiretroviral therapy (ART) — raising hope that curing HIV is a possibility.
The gap in overall life expectancy between people with HIV (PWH) and those without HIV has narrowed over time, particularly among optimally treated PWH. However, PWH still have fewer comorbidity-free years than those without HIV, according to a study presented at CROI 2020.
Children with HIV (HIV+) who switched to efavirenz had higher bone mass even after 4 years of switching compared with those who remained on an antiretroviral therapy (ART) regimen comprising lopinavir and ritonavir, according to data presented at CROI 2020.
A long-acting (LA) injectable therapeutic regimen comprising the integrase strand-transfer inhibitor cabotegravir and the nonnucleoside reverse-transcriptase inhibitor rilpivirine shows therapeutic potential over an oral antiretroviral therapy (ART) regimen in adults with HIV-1, according to the week 96 results of the phase III FLAIR* trial.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.